Robust dose summation to evaluate diaphragm motion impact in proton therapy of esophageal cancer
Richard Canters,
The Netherlands
PD-0396
Abstract
Robust dose summation to evaluate diaphragm motion impact in proton therapy of esophageal cancer
Authors: Richard Canters1, Vicki Taasti2, Gloria Vilches-Freixas3, Femke Vaassen2, Kim Van der Klugt2, Maaike Berbee2
1GROW School for Oncology, Maastricht University Medical Center+, Department of Radiation Oncology (MAASTRO), , Maastricht, The Netherlands; 2GROW School for Oncology, Maastricht University Medical Center+, Department of Radiation Oncology (MAASTRO), Maastricht, The Netherlands; 3 GROW School for Oncology, Maastricht University Medical Center+, Department of Radiation Oncology (MAASTRO), Maastricht, The Netherlands
Show Affiliations
Hide Affiliations
Purpose or Objective
Diaphragm
motion can be a significant factor influencing target coverage in irradiation
of esophageal tumors. Proton therapy is potentially more sensitive to anatomical variations than photon
radiotherapy. In this study we evaluated the dosimetric quality of
proton treatments, taking into account the patient anatomy changes during the
treatment course and the correlation with diaphragm movement changes.
Material and Methods
In
this study, 35 patients treated with proton therapy for esophageal cancer using
a 23x1.8Gy fractionation scheme were evaluated. All patients received a 4D CT
planning CT (pCT), as well as weekly repeat 4D CTs (reCT). The clinical target
volume (CTV) was delineated on each phase of the pCT, and the CTVs were
combined to an internal target volume (ITV). Three posterior beams with a
separation of 20 degrees were used, with in some patients an additional fourth
beam from anterior direction. Dose calculations were performed on the average
CT. The proton plans were robustly optimized with 5mm setup uncertainty and 3%
range uncertainty, combined with a fixed margin of 3mm around the ITV. During
treatment, all plans were re-evaluated on the reCTs using a robust evaluation
with 2mm setup uncertainty and 3% range uncertainty, accounting for residual
errors. If necessary, plans were adapted based on evaluation on the reCT. After
deformable registration to the pCT, for each robustness scenario a dose
summation was created, deforming dose from reCT to pCT. Robust dose summation
was performed by summing each scenario over all reCTs. Subsequently, voxel-wise
minimum and maximum summed dose distributions were derived. Diaphragm positions
in inhale and exhale phases of the 4D CT were extracted by measuring the
diaphragm-lung intersection at the axial center of each lung. Therefrom a baseline
diaphragm position (i.e. the average between inhale and exhale) and a diaphragm
amplitude (i.e. the difference between inhale and exhale diaphragm position)
were derived.
Results
Diaphragm
average amplitude [standard deviation (SD)] on the pCT was 1.4 [0.8] cm. The amplitude
change during treatment evaluated on each reCT was on average 0.2 [0.5] cm. The
average baseline shift observed on the repeat CTs was -0.2 [0.5] cm (Figure 1).
The average difference in voxel-wise minimum ITV D98% [SD] on repeat CTs with
respect to the planning CT was -2.7 [9.4] %. We found a weak negative
correlation between changes in ITV D98% and baseline shift (Pearson’s R = 0.54)
and no correlation with changes in amplitude. After robust dose summation, the ITV
D98% of the summed dose distributions is >94% for 32 of 35 evaluated
patients, in accordance with the 90% aimed at in the margin recipe (Figure 2).
Conclusion
Despite
changes in diaphragm amplitude up to 2.5cm and in baseline position up to 2 cm
during patient treatment, robust dose summation showed that ITV coverage in
proton therapy for esophageal cancer remained sufficient using a posterior beam
setup.